Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Alzheimer’s Disease: Market Opportunity & Major Phase 3 Treatments You Should Know

Ticker(s): LLY, AXON, BIIB

Who's the expert?

Name: Dr Todd Golde - MD

Institution: University of Florida

Bio:

  • Professor of Neuroscience at the College of Medicine University of Florida and the Director of UF’s Center for Translational Research in Neurodegenerative Disease
  • Has served as PI for several large Alzheimer's Disease clinical trials including current PI of NIH funded Alzheimer's Disease Research Center, contact PI for a large U01 grant focusing on leveraging systems biology to find new therapeutic targets for AD, and PI of R01 related to inflammation and immunotherapies for AD
  • 30+ years of research focused on AD; published extensively in peer reviewed journals and holds leadership position in several professional organizations including the National Alzheimer's Association

Interview Questions
Q1.

What is your background treating neurodegenerative disorders? How many patients do you treat with Alzheimer’s? How difficult is the disease to diagnose?

Added By: joe_mccann
Q2.

What is your background treating neurodegenerative disorders? How many patients do you treat with Alzheimer’s? How difficult is the disease to diagnose?

Added By: joe_mccann
Q3.

Generally speaking, what types of treatments do you find most exciting for AD (amyloid related, neurotransmitters, etc)?

Added By: joe_mccann
Q4.

Do you think PFE’s recent 5HT6 inhibiting AD drug failure indicates a strong likelihood of failure for AXON’s RVT-101

Added By: joe_mccann
Q5.

What are your thoughts on the science supporting the role of AB peptides in AD.

Added By: joe_mccann
Q6.

What are your thoughts on LLY, AXON, BIIB, AB, and MRK’s AD Phase 3 drug efforts? What other companies are you keeping an eye on? Why?

Added By: joe_mccann
Q7.

What drug company are you most excited about with respect to treating AD? Why?

Added By: joe_mccann
Q8.

What are the chances that you see solanezumab hitting on the primary but missing on functional endpoint? If this occurs do you think the FDA will approve without significant functional improvements?

Added By: industry pharmacist
Q9.

What would it take for an AD therapy to be curative? Are there therapeutic strategies that can reverse disease and symptoms, or do most strategies tend to try and prevent further neurodegeneration? What is your opinion on treating symptoms vs. treating root cause?

Added By: dquinlan
Q10.

Do you think there is a dose advantage for intepiridine that could lead it to succeed where Lundbeck and Pfizer's drugs failed?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.